Plevitrexed

DB06163InvestigationalSmall molecule

Investigated for use/treatment in pancreatic cancer, solid tumors, gastric cancer, lung cancer, and colorectal cancer.

Chemical structure of Plevitrexed
Primary indication
Investigated for use/treatment in pancreatic cancer, solid tumors, gastric cancer, lung cancer, and colorectal cancer.Curator reviewed
Formula / weight
C26H25FN8O4 · 532.536 g/mol (avg)
Code names
BGC-9331 · NSC-696259 · ZD-9331

Resolves to

Compound
UNIIL9P2881C3HCAS153537-73-6ChEMBLCHEMBL126648
Structure
InChIKeyIEJSCSAMMLUINT-NRFANRHFSA-NSMILESCC1=NC(=O)C2=CC(CN(CC#C)C3=CC=C(C(=O)N[C@@H](CCC4=NN=NN4)C(O)=O)C(F)=C3)=C(C)C=C2N1
Targets
P12461TMP1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
39Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Plevitrexed, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In